Treatment of chronic inflammatory diseases with biologic agents: Opportunities and risks for the elderly

Díaz-Borjón, Alejandro; Weyand, Cornelia M.; Goronzy, Jörg J.

doi:10.1016/j.exger.2006.10.010

Cited by 18 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, inhibition of TNFα may increase the risk for severe/ non-severe infections. [14][15][16][17] In conclusion, although anti-TNF treatment is quite effective in taking disease activity under control in RA and AS patients, it is always necessary to be alert due to increased risk for infection; it was revealed in this study, which attracted attention on urinary infections commonly encountered particularly in normal population, that although anti-TNF treatment increases this risk, underlying disease on its own, activity of the disease, degree of disability and other accompanying diseases may be factors that may cause predisposition to infections, and conduction of more large-scale studies is required in order to better clarify this matter.…”

Section: Discussionmentioning

confidence: 99%

Romatoid Artrit ve Ankilozan Spondilitli Hastalarda Anti-TNF İlaç Kullanımının Üriner Enfeksiyon Gelişimine Etkisi

Uçar¹,

Sayarlıoğlu²

2019

Journal of Contemporary Medicine

View full text Add to dashboard Cite

Introduction: Our objective in this study is to investigate whether there is an increase in frequency of urinary infections in patients using anti-Tumor Necrosis Factor alpha (TNFα) compared to the patients using disease-modifying anti-rheumatic drugs (DMARD). Methods: 29 patients with rheumatoid arthritis (RA) (F/M: 23/6) and 20 patients with Ankylosing Spondylitis (AS) (F/M: 3/17), for whom anti-TNF agents were initiated for the first time, and 30 healthy controls (F/M: 9/21) were included in the study. Additionally, in order to reveal effects of anti-TNF medications on development of urinary infections better, 29 RA (F/M: 26/3) and 20 AS (F/M: 6/14) patients using DMARDs were also included in the study. Results: When the differences in age, gender and marital status among RA patients were eliminated, there was no significant difference in regard to frequency of development of urinary infections between patients with active disease before anti-TNF treatment for whom initiation of anti-TND treatment was considered and the patients without active disease who were using DMARDs, despite of differences in disease activity. When the AS patients using anti-TNF agents and DMARDs were compared with the healthy control group in regard to frequency of development of urinary infections; while there was no significant difference in the DMARD group, it was more frequently encountered in the anti-TNF group at 2 nd and 3 rd visits. When the differences in age, gender, marital status and disease activity among AS patients were eliminated, anti-TNF treatment was determined to pose an additional risk for frequency of development of urinary infections compared to DMARD treatment Discussion and Conclusion: In conclusion, although anti-TNF treatment is quite effective in taking disease activity under control in RA and AS patients, it is always necessary to be alert due to increased risk for infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Romatoid Artrit ve Ankilozan Spondilitli Hastalarda Anti-TNF İlaç Kullanımının Üriner Enfeksiyon Gelişimine Etkisi

Uçar¹,

Sayarlıoğlu²

2019

Journal of Contemporary Medicine

View full text Add to dashboard Cite

show abstract

“…The most severe secondary effect of anti-TNFa was tuberculosis. 8,[18][19][20] The development of antibodies against the TNFa inhibitors is another possible problem, 5,17,18 as well as lupus-like syndrome. 9 When the first TNF antagonist fails, perhaps the best alternative is to switch to a different type of biological agent such as Abatacept or Rituximab and, in the case of adverse event to a previous treatment, to another TNF inhibitor.…”

Section: Long-term Efficacy Of Biological Agents and Their Impact On mentioning

confidence: 99%

“…7 The cost of TNFa inhibitors is one of the main limitations associated with this therapy: they are considerably more expensive than the traditional DMARDs. Considering the high cost of these drugs, several strategies of combination of these agents with DMARDs are being increasingly studied, 5,8,11 as is explained in the next section.…”

Section: Biological Agents In the Treatment Of Rheumatic Diseasesmentioning

confidence: 99%

“…Further information on the safety and efficacy of TNF blockers can be obtained, for example, in Ref. 8 The most used biological agents for the treatment of rheumatic diseases and their characteristics and secondary effects are also presented in Table 1.…”

Section: Biological Agents In the Treatment Of Rheumatic Diseasesmentioning

confidence: 99%

“…15,16 Before initiating the therapy with TNF inhibitors, some contraindications must be considered by physicians to minimize the risks including active infections, history of recurrent or chronic infections, cardiac failure, or malignancy. 8,17 The blockade of a critical proinflammatory cytokine in patients already taking other anti-inflammatory agents may trigger severe infections. The most severe secondary effect of anti-TNFa was tuberculosis.…”

Section: Long-term Efficacy Of Biological Agents and Their Impact On mentioning

confidence: 99%

See 2 more Smart Citations

Impact of Biological Agents and Tissue Engineering Approaches on the Treatment of Rheumatic Diseases

Silva

Martins

Teixeira³

et al. 2010

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

The treatment of rheumatic diseases has been the focus of many clinical studies aiming to achieve the best combination of drugs for symptom reduction. Although improved understanding of the pathophysiology of rheumatic diseases has led to the identification of effective therapeutic strategies, its cure remains unknown. Biological agents are a breakthrough in the treatment of these diseases. They proved to be more effective than the other conventional therapies in refractory inflammatory rheumatic diseases. Among them, tumor necrosis factor inhibitors are widely used, namely Etanercept, Infliximab, or Adalimumab, alone or in combination with disease-modifying antirheumatic drugs. Nevertheless, severe adverse effects have been detected in patients with history of recurrent infections, including cardiac failure or malignancy. Currently, most of the available therapies for rheumatic diseases do not have sufficient tissue specificity. Consequently, high drug doses must be administrated systemically, leading to adverse side effects associated with its possible toxicity. Drug delivery systems, by its targeted nature, are excellent solutions to overcome this problem. In this review, we will describe the state-of-the-art in clinical studies on the treatment of rheumatic diseases, emphasizing the use of biological agents and target drug delivery systems. Some alternative novel strategies of regenerative medicine and its implications for rheumatic diseases will also be discussed.

show abstract

Nanomaterials for chronic inflammatory diseases: the current status and future prospects

et al. 2021

View full text Add to dashboard Cite

Treatment of chronic inflammatory diseases with biologic agents: Opportunities and risks for the elderly

Cited by 18 publications

References 25 publications

Romatoid Artrit ve Ankilozan Spondilitli Hastalarda Anti-TNF İlaç Kullanımının Üriner Enfeksiyon Gelişimine Etkisi

Romatoid Artrit ve Ankilozan Spondilitli Hastalarda Anti-TNF İlaç Kullanımının Üriner Enfeksiyon Gelişimine Etkisi

Impact of Biological Agents and Tissue Engineering Approaches on the Treatment of Rheumatic Diseases

Nanomaterials for chronic inflammatory diseases: the current status and future prospects

Contact Info

Product

Resources

About